Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor
NCT07499362Phase 2Recruiting
- Sponsor
- Merck KGaA
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimicotinib in tenosynovial giant cell tumor (TGCT), sponsored by Merck KGaA. Started Mar 2026; status: recruiting.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT07499362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499362.